CYTOSORBENTS CORP (CTSO) Stock Income Statement
NASDAQ:CTSO - Nasdaq - US23283X2062 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.54M | 35.59M | 31.09M | 34.69M | 43.17M | |||
| Cost Of Goods | 9.77M | 10.47M | 9.13M | 13.96M | 11.05M | |||
| Gross Profit | 24.76M | 25.13M | 21.95M | 20.73M | 32.12M | |||
| Operating Expenses | 40.24M | 41.58M | 53.25M | 52.25M | 54.86M | |||
| Research and Development | 6.33M | 6.92M | 15.59M | 15.12M | 16.38M | |||
| Selling, General, and Administrative Expenses | 33.91M | 34.66M | 37.65M | 37.14M | 38.48M | |||
| Operating Income | -15.48M | -16.45M | -31.29M | -31.52M | -22.74M | |||
| Interest Income/Expense | -1.78M | -5.62M | 1.79M | -2.32M | -2.55M | |||
| Other Income/Expense | N/A | 0.00 | 96.80K | -70.00K | N/A | |||
| Non Recurring Items | N/A | -333.70K | -655.70K | N/A | N/A | |||
| Income Before Taxes | -17.53M | -22.41M | -30.06M | -33.91M | -25.29M | |||
| Income Tax | N/A | -1.69M | -813.70K | -1.09M | -740.00K | |||
| Net Income | -15.84M | -20.72M | -29.25M | -32.81M | -24.56M | |||
| EBITDA | -13.73M | -14.71M | -29.83M | -30.64M | -22.01M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.29 | -0.38 | -0.65 | -0.75 | -0.57 | |||
| Non GAAP EPS | -0.28 | -0.38 | -0.65 | -0.76 | -0.57 | |||
| Statistics | ||||||||
| Gross Profit Margin | 71.70% | 70.59% | 70.62% | 59.76% | 74.40% | |||
| Profit Margin | -45.86% | -58.21% | -94.09% | -94.58% | -56.89% | |||
| Operating Profit Margin | -44.82% | -46.22% | -100.67% | -90.86% | -52.68% | |||
All data in USD